A Phase 1, First-in-human Study of VX-634

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-634 at various doses.

Clinical Trial Description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.). ;

Study Design

Related Conditions & MeSH terms

Alpha 1-Antitrypsin Deficiency

Clinical Trial Details

NCT number	NCT05579431
Study type	Interventional
Source	Vertex Pharmaceuticals Incorporated
Contact
Status	Completed
Phase	Phase 1
Start date	October 13, 2022
Completion date	November 13, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Recruiting	`NCT03285100` - The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation	N/A
Completed	`NCT03636347` - A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.	Phase 2
Completed	`NCT00396006` - Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)	Phase 4
Completed	`NCT04174118` - Study of DCR-A1AT in Healthy Adult Volunteers	Phase 1
Recruiting	`NCT05856331` - Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Phase 2
Recruiting	`NCT00571272` - Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Completed	`NCT02168686` - Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency	Phase 1/Phase 2
Recruiting	`NCT04204252` - Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD	Phase 3
Completed	`NCT00067756` - 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?	Phase 2
Completed	`NCT00295061` - Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults	Phase 3
Completed	`NCT00001462` - Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals	N/A
Active, not recruiting	`NCT05297812` - Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
Completed	`NCT03114020` - Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency	Phase 2
Completed	`NCT00460096` - Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency	Phase 2/Phase 3
Completed	`NCT00377416` - Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency	Early Phase 1
Terminated	`NCT00005098` - Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency	N/A
Completed	`NCT03362242` - Study of ARO-AAT in Normal Adult Volunteers	Phase 1
Not yet recruiting	`NCT05897424` - Open Label Extension Study of INBRX-101 in Adults With AATD Emphysema	Phase 2
Completed	`NCT00301366` - The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency	Phase 3